Circulation highlights a phase 2 randomized trial where memantine reduced premature atrial contractions, lowered non sustained atrial tachycardia, and cut new onset atrial fibrillation risk, suggesting a glutamatergic pathway target for atrial arrhythmias.
In a Phase 2 RCT, antagonism of NMDA receptors with memantine reduced premature atrial contractions
lowered non-sustained atrial tachycardia
cut new-onset AF risk, highlighting a novel glutamatergic pathway for atrial arrhythmia therapy.
In a Phase 2 RCT, antagonism of NMDA receptors with memantine reduced premature atrial contractions, lowered non-sustained atrial tachycardia & cut new-onset AF risk, highlighting a novel glutamatergic pathway for atrial arrhythmia therapy.
This finding is one of many signals tracked across Healthcare. The live feed updates every few hours with new authority voices, debates, and emerging ideas.
← Back to Healthcare